ARS Pharmaceuticals, Inc. Common Stock (SPRY) Stock Price

SPRYStock

$5.89−54.20%52W

Market Cap$585.74M

P/E102.30x

PEG Ratio—

Div yield—

Beta0.81

SPRY Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-47.49%

Price vs S&P 500 (4W)6.33%

VGM Score43.52

P/E Ratio (Annual)102.30x

P/CF (Annual)60.39x

Book Value / Share (Quarterly)$0.62

P/TBV (Annual)11.54x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)299.68%

Cash Flow / Share (Quarterly)$-1.77

Price vs S&P 500 (YTD)-62.26%

Gross Margin (TTM)74.12%

Net Profit Margin (TTM)-200.00%

EPS (TTM)$-2.00

10-Day Avg Trading Volume1.62M

EPS Excl Extra (TTM)$-2.00

EPS (Annual)$-1.74

ROI (Annual)-81.33%

Gross Margin (Annual)76.72%

Cash / Share (Quarterly)$2.02

Revenue Growth QoQ (YoY)184.47%

P/E Normalized (Annual)102.30x

ROA (Last FY)-52.28%

Revenue Growth TTM (YoY)1.92%

EBITD / Share (TTM)$-2.03

ROE (5Y Avg)-42.32%

Operating Margin (TTM)-204.49%

Cash Flow / Share (Annual)$-1.72

P/B Ratio9.88x

P/B Ratio (Quarterly)13.01x

Net Income / Employee (Annual)$-1,084,200

EV / Revenue (TTM)6.85x

Net Interest Coverage (TTM)-64.94x

ROA (TTM)-60.85%

EV / EBITDA (TTM)102.89x

EPS Incl Extra (Annual)$-1.74

Current Ratio (Annual)7.28x

Quick Ratio (Quarterly)4.63x

3-Month Avg Trading Volume2.00M

52-Week Price Return-54.20%

EV / Free Cash Flow (Annual)65.84x

Revenue / Employee (TTM)$626,500

Tangible BV / Share (Quarterly)$0.47

P/S Ratio (Annual)7.19x

Asset Turnover (Annual)0.26x

52-Week High$13.46

EPS Excl Extra (Annual)$-1.74

CapEx CAGR (5Y)-18.10%

26-Week Price Return-35.56%

Quick Ratio (Annual)6.91x

13-Week Price Return-37.34%

Total Debt / Equity (Annual)0.84x

Current Ratio (Quarterly)4.94x

Enterprise Value$677.95M

Asset Turnover (TTM)0.30x

Revenue / Employee (Annual)$533,400

Pretax Margin (Annual)-203.35%

Cash / Share (Annual)$2.47

3-Month Return Std Dev87.53%

Net Income / Employee (TTM)$-1,253,000

ROE (Last FY)-149.92%

Net Interest Coverage (Annual)-19.24x

EPS Basic Excl Extra (Annual)$-1.74

Receivables Turnover (TTM)5.21x

Total Debt / Equity (Quarterly)1.57x

EPS Incl Extra (TTM)$-2.00

ROI (TTM)-98.41%

P/S Ratio (TTM)6.12x

Revenue / Share (Annual)$0.85

Tangible BV / Share (Annual)$1.01

Price vs S&P 500 (52W)-72.76%

Year-to-Date Return-49.44%

5-Day Price Return10.09%

EPS Normalized (Annual)$-1.74

ROA (5Y Avg)-22.49%

Net Profit Margin (Annual)-203.25%

Month-to-Date Return14.81%

Cash Flow / Share (TTM)$-0.24

EBITD / Share (Annual)$-1.81

Operating Margin (Annual)-212.92%

LT Debt / Equity (Annual)0.84x

ROI (5Y Avg)-28.60%

LT Debt / Equity (Quarterly)1.57x

EPS Basic Excl Extra (TTM)$-2.00

P/TBV (Quarterly)16.92x

P/B Ratio (Annual)10.08x

Inventory Turnover (TTM)3.18x

Pretax Margin (TTM)-200.08%

Book Value / Share (Annual)$1.15

Price vs S&P 500 (13W)-39.30%

Beta0.81x

P/FCF (Annual)46.65x

Revenue / Share (TTM)$1.00

ROE (TTM)-153.61%

52-Week Low$4.91

vGradeD

gGradeB

mGradeD

vgmGradeC

SPRY Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.49	-$0.63	-27.70%(-$0.14)
Q1 2026	May 15, 2026	-$0.54	-$0.61	-14.02%(-$0.07)
Q4 2025	Mar 9, 2026	-$0.48	-$0.42	+12.50%(+$0.06)
Q3 2025	Nov 10, 2025	-$0.49	-$0.52	-6.12%(-$0.03)
Q2 2025	Aug 13, 2025	-$0.52	-$0.46	+10.68%(+$0.05)

SPRY Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.38

4.36

4.40

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
SPRYARS Pharmaceuticals, Inc. Common Stock	D	B	D	$5.89
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About ARS Pharmaceuticals, Inc. Common Stock

ARS Pharmaceuticals commercializes Neffy, a needle-free intranasal epinephrine treatment for Type 1 allergic reactions and anaphylaxis. The proprietary formulation combines epinephrine with an absorption enhancer to deliver efficacy comparable to injectable alternatives. Neffy is marketed globally under different trade names, including EURneffy in the European Union and United Kingdom.